394 related articles for article (PubMed ID: 2665082)
1. Current perspectives in the treatment of thrombotic disorders.
Drouet L; Caen JP
Semin Thromb Hemost; 1989 Apr; 15(2):111-22. PubMed ID: 2665082
[TBL] [Abstract][Full Text] [Related]
2. Current trends in antithrombotic drug and device development.
Fareed J
Semin Thromb Hemost; 1996; 22 Suppl 1():3-8. PubMed ID: 8807721
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.
Jespersen J
Dan Med Bull; 1988 Feb; 35(1):1-33. PubMed ID: 3277796
[TBL] [Abstract][Full Text] [Related]
4. Blood viscosity and thrombosis: clinical considerations.
Smith BD; La Celle PL
Prog Hemost Thromb; 1982; 6():179-201. PubMed ID: 6762612
[TBL] [Abstract][Full Text] [Related]
5. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
Jennings LK
Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis.
Diquélou A; Dupouy D; Cariou R; Sakariassen KS; Boneu B; Cadroy Y
Thromb Haemost; 1995 Nov; 74(5):1286-92. PubMed ID: 8607111
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.
Chesebro JH; Webster MW; Zoldhelyi P; Roche PC; Badimon L; Badimon JJ
Circulation; 1992 Dec; 86(6 Suppl):III100-10. PubMed ID: 1424043
[TBL] [Abstract][Full Text] [Related]
9. [Effects of thrombolysis on platelets and coagulation].
Helft G; Abdelouahed M; Vacheron A; Lecompte T; Samama MM
Ann Cardiol Angeiol (Paris); 1995 Sep; 44(7):354-60. PubMed ID: 8561440
[TBL] [Abstract][Full Text] [Related]
10. [Thrombosis and its therapeutic targets].
Drouet L
Rev Prat; 1999 Oct; 49(15):1617-23. PubMed ID: 10581991
[TBL] [Abstract][Full Text] [Related]
11. A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding.
Buchanan MR; Brister SJ
Wien Klin Wochenschr; 1999 Feb; 111(3):81-9. PubMed ID: 10093889
[TBL] [Abstract][Full Text] [Related]
12. [Thrombogenic properties of the vessel and their inhibition].
Cazenave JP; Klein-Soyer C; Beretz A
Nouv Rev Fr Hematol (1978); 1982; 24(3):167-71. PubMed ID: 6752880
[TBL] [Abstract][Full Text] [Related]
13. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
Schrör K
Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
[TBL] [Abstract][Full Text] [Related]
14. A guide for diagnosis of patients with arterial and venous thrombosis.
Quinn C; Hill J; Hassouna H
Clin Lab Sci; 2000; 13(4):229-38. PubMed ID: 11586510
[TBL] [Abstract][Full Text] [Related]
15. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
17. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L
Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation.
Harker LA; Hanson SR; Kelly AB
Thromb Haemost; 1997 Jul; 78(1):736-41. PubMed ID: 9198248
[TBL] [Abstract][Full Text] [Related]
19. Protein C.
Esmon CT
Prog Hemost Thromb; 1984; 7():25-54. PubMed ID: 6099583
[TBL] [Abstract][Full Text] [Related]
20. Use of thromboelastography PlateletMapping to monitor antithrombotic therapy in a patient with Budd-Chiari syndrome.
James K; Bertoja E; O'Beirne J; Mallett S
Liver Transpl; 2010 Jan; 16(1):38-41. PubMed ID: 20035517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
